<unk>  is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults.<unk>  is provided as a subcutaneous injection of 100 mg given every eight weeks (except for the second dose, which is given four weeks after the first dose).
Guselkumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Dupilumab
Tralokinumab
Alirocumab